AI Article Synopsis
- Induced pluripotent stem cell (iPSC) technology, developed in 2006, allows somatic cells to be reprogrammed into pluripotent stem cells using specific transcriptional factors.
- iPSCs can theoretically differentiate into any cell type, making them valuable for clinical research and studies on disease mechanisms.
- The article discusses the progress in iPSC research from a pathologist's viewpoint, highlighting the potential for disease modeling using techniques like organoid differentiation, as well as the challenges that still need to be addressed.
Article Abstract
Induced pluripotent stem cell (iPSC) technology was originally developed in 2006. Essentially, it converts somatic cells into pluripotent stem cells by transiently expressing a few transcriptional factors. Once generated, these iPSCs can differentiate into all the cell types of our body, theoretically, which has attracted great attention for clinical research including disease pathobiology studies. Could this technology then become an additional research or diagnostic tool widely available to practicing pathologists? Here we summarize progress in iPSC research toward disease pathobiology studies, its future potential, and remaining problems from a pathologist's perspective. A particular focus will be on introducing the effort to recapitulate disease-related morphological changes through three-dimensional culture of stem cells such as organoid differentiation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5918271 | PMC |
| http://dx.doi.org/10.1038/labinvest.2017.81 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!